NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity

Qijiong Li\textsuperscript{1\dagger}, Xiaofeng Liu\textsuperscript{2\dagger}, Kemin Jin\textsuperscript{3}, Min Lu\textsuperscript{4}, Chunfeng Zhang\textsuperscript{2}, Xiaojuan Du\textsuperscript{2} and Baocai Xing\textsuperscript{3*}

Abstract

Background: N-acetyltransferase 10 (NAT10) is a histone acetyltransferase which is involved in a wide range of cellular processes. Recent evidences indicate that NAT10 is involved in the development of human cancers. Previous study showed that NAT10 acetylates the tumor suppressor p53 and regulates p53 activation. As \textit{Tp53} gene is frequently mutated in hepatocellular carcinoma (HCC) and associates with the occurrence and development of HCC, the relationship between NAT10 and HCC was investigated in this study.

Methods: Immunohistochemistry (IHC) and western blot analysis were performed to evaluate the NAT10 expression in HCC. Immunoprecipitation experiments were performed to verify the interaction of NAT10 with mutant p53 and Mdm2. RNA interference and Western blot were applied to determine the effect of NAT10 on mutant p53. Cell growth curve was used to examine the effect of NAT10 on HCC cell proliferation.

Results: NAT10 was upregulated in HCC and increased NAT10 expression was correlated with poor overall survival of the patients. NAT10 protein levels were significantly correlated with p53 levels in human HCC tissues. Furthermore, NAT10 increased mutant p53 levels by counteracting Mdm2 action in HCC cells and promoted proliferation in cells carrying p53 mutation.

Conclusion: Increased NAT10 expression levels are associated with shortened patient survival and correlated with mutant p53 levels. NAT10 upregulates mutant p53 level and might enhance its tumorigenic activity. Hence, we propose that NAT10 is a potential prognostic and therapeutic candidate for p53-mutated HCC.

Keywords: NAT10, Hepatocellular carcinoma, Prognosis, Mutant p53, Stability

Background

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies throughout the world and has been the third leading-cause of cancer-related death worldwide [1]. The mechanisms involved in the development and progression of HCC remain poorly understood. In recent years, the relationship between the somatic mutations and HCC was further elucidated by the identification of crucial genes and pathways in HCC [2]. Wnt/β-catenin was found to be the most frequently mutated pathway, while the p53 pathway was considered to be the second most frequently mutated pathway in HCC, with the occurrence about 21% in HCC [3–5]. Nevertheless, the mechanism of how genetic changes lead to pathological and physiological changes is still unclear. Therefore, the further exploration of the mechanisms of how genetic mutations lead to hepatic tumorigenesis require further study.

p53, a key tumor repressor, plays a vital role in various critical cellular processes, including DNA repair, cell cycle regulation, apoptosis induction, etc. [6, 7]. \textit{TP53} mutations were frequently observed in human cancers and various studies have indicated that some mutant p53 proteins facilitate tumorigenesis [8, 9]. Mutant p53 exhibits a wide range of distinct change of genetic structures which lead to altered heat stability, and lose

\textsuperscript{*} Correspondence: xingbaocai88@sina.com
\textsuperscript{†}Equal contributors
\textsuperscript{3}Hepatopancreatobiliary Surgery Department I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China

Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
the ability to bind p53–responding elements and trans-activate downstream genes [10]. Moreover, mutant p53 exhibits characteristic of oncogene such as loss of cell growth control and gain functions in promoting tumorigenesis [11–13]. Previous studies found that the Tp53 gene mutations are frequently observed in HCC, and these mutations were correlated with stage and prognosis of tumor [4, 5]. Recent study has shown that compared with HCC patients without detectable p53 mutations, patients carrying Tp53 mutations suffer poor prognosis of higher recurrence rate and shorter overall survival [14]. Given the pivotal role of mutant p53 in tumorigenesis, some strategies to target p53 mutations have been developed in order to treat HCC [15–19]. Accordingly, these findings indicate that mutant p53 is a relatively key role in the pathogenesis of HCC. Therefore, further study to understand the modulations and functional changes of mutant p53 in HCC is essential.

N-acetyltransferase 10 (NAT10; named as hALP as well), is a member of the Gcn5-related N-acetyltransferase family of histone acetyltransferases (HATs). Previous study showed that truncated recombinant NAT10 (amino acids 164–834) acetylates calf thymus histones in vitro [20]. NAT10 is located in the nucleolus and involved in the regulation of telomerase activity, rRNA transcription, and cytokinesis [21–24]. The NAT10 inhibitor, remodelin, can be used to ameliorate laminopathies through correcting nuclear architecture and attenuating senescence [25]. Recent reports demonstrated that NAT10 enhances p53 activity through acetylating p53 and counteracting Mdm2 action in response to DNA damage [26]. Given its pivotal role in p53 activation, the aim of this study was to investigate whether NAT10 can regulate mutant p53 activity.

**Methods**

**Cell culture and transfections**

The hepatoma cell lines Huh7 (mutant p53 Y220C) was obtained from COBIOER BIOSCIENCES CO., LTD (COBIOER, Nanjing, China) and HepG2 (wild-type p53), MHCC-97H (R249S), MHCC-97 L (R249S) and the normal hepatic cell line LO2 (wild-type p53) were gifts from Prof. Curtis C. Harris. Liver cancer cells were cultured and maintained in Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% fetal bovine serum at 37 °C in a humidified atmosphere containing 5% CO2. Cells were transfected with plasmid DNA or siRNA duplexes by using Lipofectamine™ 2000 (Invitrogen, CA, USA) according to the manufacturer’s protocol. For silencing NAT10 expression, a small interfering RNA (siRNA) targeting NAT10 (sequence: 5′-CAGGACGACAGGCGAG AAUGAGA-3′), Mdm2 (sequence: 5′-AAGCCAUGGGCUUUUGAUGUA-3′) was synthesized, together with the control siRNA (5′-ACUACCGUGGAAUAGGGUG-3′; Shanghai GenePharma Co., Ltd).

**Plasmids and antibodies**

FLAG-tagged NAT10 and NAT10 mutants were cloned into pCI-neo. Anti-p53 (DO-1), anti-actin (C-11), anti-Mdm2 (SMP14) and anti-p21 (817) antibodies were purchased from Santa Cruz Biotechnology, Inc. Anti-Flag (F3165) antibody was purchased from Sigma. Anti-NAT10 antibody was a gift from Dr. B. Zhang.

**Preparation of cellular extracts**

Preparation of cellular extracts was performed as described previously [26]. In Brief, cells were harvested and washed with PBS. Then, cells were lysed in ice-cold H lytic buffer A (10 mM Tris-HCl pH 7.4, 10 mM KCl, 2 mM MgCl2, 0.05% TritonX-100, 1 mM DTT, 1 mM EDTA and fresh protease inhibitors). Next, the nuclear pellet was collected after centrifugation for 10 min at 2000 rpm, and the supernatant was collected as the cytoplasmic extract. The crude nuclear pellet was suspended in T Lysis Buffer (20 mM HEPES pH 7.9, 420 mM NaCl, 0.2 mM EDTA, 1.5 mM MgCl2, 0.5 mM DTT, and 10% glycerol with protease inhibitor mixture) and swollen at 4 °C for 30 min. The homogenate was centrifuged for 15 min at 12000 rpm. Nuclear and cytoplasmic fractions were subjected to Western blot using the indicated antibodies.

**Immunoblotting**

Total proteins were extracted and immunoblotting was performed as the standard procedures. Then, the immunoreactivity was detected with ECL Western blot Detection Reagent (GE Healthcare).

**Immunoprecipitation assay**

Immunoprecipitation assay was performed as described previously [27]. In brief, Huh7 cellular lysates were prepared in lysis buffer A (25 mM Tris-HCl pH 7.5, 100 mM KCl, 1 mM DTT, 2 mM EDTA, 0.5 mM phe-nylmethylsulfonyl fluoride, and 0.1% Nonidet P-40). Cellular extracts were obtained by centrifugation for 30 min at 12000 rpm. Specific antibodies were incubated with 15 ul protein A and G beads (Amersham Biosciences) in IPP500 (500 mM NaCl, 10 mM Tris- HCl pH 8.0, 0.1% Nonidet P-40). Coupled beads were incubated with cellular extracts for 2 h at 4 °C. After extensive washes, the precipitated proteins were subjected to Western blotting.

**Cell growth assay**

Cell growth curve was analyzed using the Cell Counting Kit-8 (CCK-8, Dojindo) according to the manufacturer’s directions. Briefly, Huh7 or MHCC-97 L cells were transfected with the indicated siRNAs (500 cells per well) and grew in 10% serum containing media. Cell numbers were estimated at day 0, 1, 2, 3, 4 and 5. The
growth curve shows the mean ± standard deviation from three technical replicates.

Patients and tumor tissues
Human HCC tissues and adjacent noncancerous tissues for western blotting were obtained from 19 patients with HCC who underwent tumor resection at the Beijing Cancer Hospital. After resection, specimens were rinsed thoroughly in ice-cold normal saline and stored in liquid nitrogen.

Sections were obtained from 119 formalin-fixed, paraffin-embedded human HCC tissues and corresponding non-cancerous tissues of the same patient undergoing surgical resection without prior neoadjuvant therapy between January 2003 and October 2006 in the Beijing Cancer Hospital. The clinico-pathological patient characteristics are summarized in Table 1.

Immunohistochemistry assay
Sections (4 μm thick) were dewaxed in xylene and gradually rehydrated. After antigen retrieval, endogenous peroxidases were blocked with 3% hydrogen peroxide. Then, the sections were incubated with 10% goat serum for 30 min at room temperature. Sections were incubated with rabbit anti-NAT10 polyclonal antibody at 4 °C overnight and then with HRP-conjugated goat anti-rabbit IgG (Zhongshan Golden bridge Biotechnology, Beijing, China) at 37 °C for 30 min. Immunocomplexes were visualized by using 3,3-diaminobezidine (Dako, CA, USA). Slides were counterstained with light hematoxylin, dehydrated, and cover-slipped.

Histological slides were assessed by two independent observers, including an experienced pathologist, blinded to all clinical, pathological, and outcome information. The score discrepancies were discussed to achieve a consensus. Immunostaining was categorized into four groups: negative (0 score), 0%–10% positive cells; faintly positive (1 score), 10%–25% positive cells; moderately positive (2 scores), 25–50% positive cells; and highly positive (3 scores), ≥50% positive cells.

Statistical analysis
All statistical analyses were carried out using SPSS version 17 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism (GraphPad Software). All data are shown as mean ± standard deviation. To compare the experimental groups, Student’s t-test and one-way analysis of variance were used. Associations between NAT10 immunohistochemical staining and clinico-pathological variables were analyzed using the Mann-Whitney U test. Survival was estimated using the Kaplan–Meier method, and the difference between the survival curves was analyzed using the log-rank test. Univariate and multivariate survival analyses were performed using the Cox proportional hazards model.

Results
NAT10 is upregulated in HCC patients and is correlated with shorter survival
To determine the significance of NAT10 in hepatocellular carcinomas, we performed immunoblotting on human HCC tissues and their matched noncancerous tissues. Fourteen of 19 (73.7%) tumor samples showed increased NAT10 protein levels compared with their respective paired noncancerous tissue (Fig. 1a). These data indicated a positive correlation of NAT10 expression with HCC.

Next, we investigated the correlation of NAT10 expression with HCC progression. Immunohistochemical staining was performed to evaluate NAT10 expression on primary human tumors from a large cohort of HCC patients (n = 119). Among these 119 patients, all biopsy specimens contained both tumors and matched non-tumorous tissues. Consistent with our previous study, NAT10 was expressed in the nuclei of human HCC tumor cells (Fig. 2a). For further evaluation of the expression level of NAT10, the staining level was graded and scored from 0 to 3. According to the staining score,
all patients was subgrouped as weak expression (staining score 0–1) versus strong expression (staining score 2–3). Strong expression of NAT10 was detected in 101 of 119 cases (84.8%) of HCC tumor tissues, whereas NAT10 expression was not detected in their benign counterparts (Fig. 2b and c). Thus, NAT10 expression was significantly upregulated in HCC tumor tissues compared with their non-tumorous counterparts.

The correlation between NAT10 expression and clinico-pathological variables was analyzed using SPSS version 17. As shown in Table 1, NAT10 expression was significantly correlated with vascular invasion ($p < 0.05$). However, NAT10 expression did not correlate significantly with age, $\alpha$-fetoprotein (AFP) levels, capsular formation, tumor number, margin status and Edmondson-Steiner grade. In addition, as indicated by Kaplan-Meier analysis, high level expression of NAT10 was associated with shorter overall survival (OS; Fig. 2d) in our cohort ($p < 0.01$). According to this result, we further investigated whether NAT10 expression can affect the prognosis of HCC patients independently. Univariate analysis by Cox-regression revealed that 5 prognostic factors affecting OS: NAT10 expression level, tumor size, tumor number, microvascular invasion and lymph node metastasis. Multivariate analysis by cox-regression revealed that NAT10 expression, tumor number, microvascular invasion, and lymph node metastasis were independent prognostic factors of OS (Table 2). These data demonstrated that NAT10 is an independent prognostic factor for HCC patients.

**Increased NAT10 expression level is correlated with p53 protein level in HCC**

A previous study had demonstrated that NAT10 regulates p53 activation [26] and that p53 is frequently mutated in HCC [14]. Therefore, we next investigated whether NAT10 regulates mutant p53 activity in HCC. We compared the NAT10 and p53 protein levels from surgically removed human HCC samples by using immunoblotting. As shown in Fig. 3a and b, p53 was upregulated in 16 of 19 (84.2%) tumor samples, indicating that these tumor samples carry p53 mutations. Notably, we found that NAT10 and p53 levels was positively correlated ($r^2 = 0.4$, $p = 0.03$) in the tumor samples with co-upregulation of NAT10 and p53 (Fig. 3c). NAT10 protein levels were also positively correlated with p53 in the HCC cell lines (Fig. 3d). Together, the results above indicate that increased NAT10 expression is correlated with p53 level in HCC.
NAT10 enhances mutant p53 stability

To understand the molecular mechanism by which NAT10 regulates mutant p53 in HCC, we investigated whether NAT10 interacts with mutant p53. Extract from cytoplasm and nucleus were fractionated and subjected to Western blotting to evaluate NAT10 expression. As shown in Fig. 4a, NAT10 was detected in the nuclear extracts. Immunofluorescence staining showed that NAT10 was partially colocalized with p53 in the nucleoli (Fig. 4b). Co-immunoprecipitation confirmed that NAT10 bound to mutant p53 in the HCC cell line Huh7 carrying the p53 mutation (Fig. 4c). These findings indicate that NAT10 interacts with mutant p53.

Given the fact that NAT10 regulates p53 activity and in light of our findings that NAT10 level is correlated with mutant p53 level in HCC, we hypothesized that NAT10 also regulates mutant p53 stability. In agreement with our hypothesis, depletion of NAT10 decreased mutant p53 levels; however, no alteration of p21 levels was observed (Fig. 4d). This result was consistent with previous reports that mutant p53 loses the ability to activate wild-type p53 target genes [28, 29]. Furthermore, knockdown of NAT10 increased ubiquitination of mutant p53 (Fig. 4e), indicating that NAT10 regulates mutant p53 ubiquitination and stability. Recent reports suggest that mutant p53 is still under the regulation of Mdm2 [30, 31] and NAT10 modulates Mdm2 activity. Thus, we next analyzed whether NAT10 regulates p53 stability by counteracting Mdm2 action. As shown in Fig. 4f, ectopic expressed Mdm2 could enhance mutant p53 ubiquitination, indicating that Mdm2 could still target mutant p53 to decompose. Importantly, coexpression of NAT10 counteracted the Mdm2-induced ubiquitination of mutant p53 (Fig. 4f). Moreover, the deletion mutant NAT10-D5, which lost the ability to inhibit Mdm2 activity, failed to do so (Fig. 4f, lane 3 vs. lane 4). In addition, NAT10 had no effect on mutant p53 stability in Mdm2-depleted cells (Fig. 4g). The interaction between Mdm2 and NAT10 was further verified by co-immunoprecipitation (Fig. 4h). Taken together, these
data indicated that NAT10 regulates mutant p53 stability through counteracting Mdm2 action. Given that mutant p53 often displays acquisition of the ability to potentiates cell proliferation [32], we investigated whether increased NAT10 in cells with mutant p53 could be advantageous to cell proliferation, in contrast to cells with wild-type p53. As expected, downregulation of NAT10 in Huh7 cells resulted in decreased cell proliferation (Fig. 4i). The results were confirmed in MHCC-97 L cells which also carry mutant p53. Overexpression of NAT10 in MHCC-97 L cells enhanced cell proliferation, while ectopic expression of NAT10 had little effect on cell proliferation in p53-depleted MHCC-97 L cells (Fig. 4j). Thus, NAT10 promotes cell proliferation in cells expressing mutant p53. Together, our findings demonstrated that NAT10 regulates mutant p53 and promotes cell proliferation in cells carrying mutant p53.

**Discussion**

NAT10 has been observed to function in a variety of cellular processes which are vital to cell growth and proliferation [33, 34]. Besides, it has been indicated that NAT10 involves in affecting the nuclear architecture for the recent work found that NAT10 is the target of the small molecule “Remodelin” which can be used to treat premature aging syndromes by correcting nuclear architecture [25]. Moreover, NAT10 is downregulated in human colorectal cancer [26]. Thus, functional studies of NAT10 will be helpful for the further study of the development and occurrence of cancer. The present study provides experimental evidences that NAT10 is overexpressed in HCC and that NAT10 level is positively correlated with tumor stage. Significantly, shortened OS was observed in correlation with strong NAT10 expression. Multivariate Cox regression analysis further confirmed that NAT10 expression is an independent prognostic factor of HCC. The results from our study cohort suggest that NAT10 may be a tumor promotive factor in HCC occurrence and development. Therefore, we propose that protein quantification of NAT10 in HCC could be used in combination with pathological examination to predict the biological behaviors of HCC. The combination might be useful in the optimization of personalized treatment.

**Table 2** Univariate and multivariate analyses of factors associated with prognosis in 119 HCCs

| Clinicopathological characteristics | N  | Univariable analysis | Multivariable analysis |
|------------------------------------|----|----------------------|------------------------|
|                                    |    | RR (95% CI)          | p                      |
| Age                                |    | 0.828 (0.456–1.506)  | 0.537                  |
| <=60                               | 89 |                      | 0.800 (0.424–1.510)    | 0.492 |
| >60                                | 30 |                      |                        |      |
| Tumor size (cm)                    |    | 1.976 (1.183–3.301)  | 0.009                  |
| <5                                 | 62 |                      | 1.153 (0.628–2.116)    | 0.646 |
| >=5                                | 57 |                      |                        |      |
| Serum AFP, ng/ml                   |    | 1.876 (1.080–3.258)  | 0.026                  |
| <=20                               | 46 |                      | 1.853 (1.002–3.427)    | 0.049 |
| >20                                | 73 |                      |                        |      |
| Tumor number                       |    | 2.840 (1.605–5.025)  | <0.001                 |
| 1                                 | 97 |                      | 2.409 (1.292–4.491)    | 0.006 |
| >1                                 | 22 |                      |                        |      |
| Tumor encapsulation                |    | 0.594 (0.357–0.987)  | 0.044                  |
| No                                 | 58 |                      | 0.593 (0.342–1.029)    | 0.063 |
| Yes                                | 61 |                      |                        |      |
| Microvascular invasion             |    | 3.585 (2.140–6.006)  | <0.001                 |
| No                                 | 88 |                      | 1.928 (1.100–3.379)    | 0.022 |
| Yes                                | 31 |                      |                        |      |
| Lymph node metastasis              |    | 10.727 (3.909–29.439)| <0.001                 |
| No                                 | 114|                      | 5.862 (1.854–18.538)   | 0.003 |
| Yes                                | 5  |                      |                        |      |
| Edmondson-Steiner grade            |    | 1.366 (0.786–2.373)  | 0.269                  |
| ES = 1 ~ 2                         | 88 |                      | 1.068 (0.569–2.004)    | 0.838 |
| ES = 3 ~ 4                         | 31 |                      |                        |      |
| NAT10 expression (weak v.s. strong)|    | 6.203 (1.922–20.017) | 0.002                  |
| 0–1                                | 18 |                      | 5.201 (1.492–18.138)   | 0.010 |
| 2–3                                | 101|                      |                        |      |

**NAT10 expression** was determined by immunohistochemical staining as described in the Methods. Clinico-pathological factors were recorded as mentioned above, and the overall survival of patients was acquired by postoperative follow-up. The univariate analysis suggested that tumor size, tumor number, vascular invasion, lymph node metastasis, and NAT10 expression levels were associated with the overall survival of HCC patients. Then, we employed multivariate Cox regression analysis to identify factors that were independently correlated with patient survival. Tumor size was eliminated, and the remaining factors, including vascular invasion, tumor numbers, lymph node metastasis, and strong expression of NAT10, were identified as independent prognostic risk factors.
in cells expressing wild-type p53, indicating that NAT10 could inhibit tumorigenesis through regulating p53 [26]. Here, we report that NAT10 also promotes cell proliferation in cells expressing mutant p53 and increased NAT10 expression correlates with p53 levels in HCC. It is noteworthy that most tumors were observed overexpression of mutant p53, including HCCs [9]. Nevertheless, the underlying mechanisms remain unclear. Recent evidences indicated that the downregulated Mdm2 may be one of the causes for overexpression of mutant p53 [30]. Our results suggest that NAT10 increases mutant p53 stability and promotes cell growth in Huh-7 cells carrying mutant p53. Further, we observed that NAT10 inhibits Mdm2-mediated p53 ubiquitination in Huh-7 cells, indicating that NAT10 regulates both wild-type p53 and mutant p53 stability through counteracting Mdm2 actin. Besides, another chaperone-associated E3 ligase, CHIP was believed to play a vital role for mutant p53 degradation [35]. Thus, it’s unknown whether NAT10 regulates CHIP activity in mutant p53 degradation.

Depletion of NAT10 promotes cell proliferation in cells with wild-type p53 background but decreases cell growth in Huh-7 cells carrying mutant p53. Importantly, NAT10 is overexpressed in HCCs and overexpression of NAT10 is correlated with shortened survival. Moreover, previous study reported that NAT10 plays an important role in the growth of a subtype of epithelial ovarian cancer with poor prognosis [36]. Therefore, the role of NAT10 in tumorigenesis and cancer progression may vary in different types of tumors. Further investigations, especially animal experiments, are highly necessary to understand the pathophysiological role of NAT10 in tumor initiation and progression.

Most tumors especially HCC have observable genetic changes. Mutated or functional deficient p53 was one of the most prevalent events observed and mutations of p53 are mainly missense point mutations in the DNA-binding domain [37, 38]. Such mutations abrogate transcription of p53 target genes, thereby disrupting the tumor-suppressing activities of p53. Additionally, the proteins generated by mutated Tp53 gene acquire
Fig. 4 (See legend on next page.)

Li et al. BMC Cancer (2017) 17:605
Page 8 of 10
oncogenic functions by endowing cells with proliferation and growth advantage [39]. In vivo experiments have revealed that tumors in mice with mutant p53 had the characteristic of higher malignancy, rapid development and more invasive compared with wild type or null p53 mice [40, 41]. Thus, novel strategies are being developed aiming at tumors with mutant p53 [17, 42]. Abrogation of histone deacetylase HDAC6-binding could cause the heat-shock proteins disassociated from mutant p53, with the result that mutant p53 is easier to be degraded by Mdm2. Thus, HDAC inhibitors such as SAHA has the potential in promoting mutant p53 degradation and removing mutant p53 [43, 44]. Small molecule activators of Sirt1 have also been used to reduce mutant p53 levels [45]. NAT10 is upregulated in HCC, and it enhances p53 stability, indicating that NAT10 might be a potential target in HCC therapy. Abrogation of the interaction between NAT10 and p53 would be beneficial for tumor therapy of hepatic cancers carrying p53 mutations. These possibilities need to be examined in future studies.

**Conclusions**

Our study demonstrated that NAT10 is upregulated in HCC and that increased NAT10 expression levels are associated with shortened patient survival. Moreover, NAT10 interacts with mutant p53 and increases its stability, resulting in increased cell proliferation in HCC cells. These results indicate that NAT10 is a potential therapeutic candidate for p53-mutated HCC.

**Abbreviations**

CHIP: Carboxyl terminus of Hsc70-interacting protein; HADC: Histone deacetylase; HCC: Hepatocellular carcinoma; Hsp90: Heat shock protein 90; IHC: Immunohistochemistry; Mdm2: Murine double minute2; NAT10: N-acetyltransferase 10; OS: Overall survival; PBS: Phosphate buffered solution; SAHA: Suberoylanilide hydroxamic acid

**Acknowledgements**

We would like to thank all participants for their support in this study.

**Funding**

This work was supported by grants from the National Natural Science Foundation of China (Grant No. 81371888 and 81672735). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Availability of data and materials**

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

**Authors’ contributions**

QJ and XFL carried out the experimental procedure and data collecting, analyzing, literature reviewing and participated in writing the manuscript. KMJ provided the follow up data of the patients, contributed in interpretation of the data and were involved in the revision of the manuscript. ML, CFZ and XJD carried out the pathological diagnose and classification works, performed the statistical analysis, participated in the design of the study and were involved in the revision of the manuscript. BCX conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the ethics committee of Peking University School of Oncology (Beijing Cancer Hospital and Institute), and was performed in accordance with the Helsinki Declaration of 1975, as revised in 1983. All the patients enrolled were comprehensively informed, and written informed consent to participate in this research and publish the data were obtained.

**Consent for publication**

Not Applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China.
2. Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
3. Hepatopancreatobiliary Surgery Department I, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University School of Oncology, Beijing Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China. 4. Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
References

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533–43.
2. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012;44(6):694–8.
3. Martin J, Dufour JR. Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol. 2008;14(11):1720–33.
4. Sell S. Mouse models to study the interaction of risk factors for human liver cancer. Cancer Res. 2003;63(22):7553–62.
5. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48(6):2047–63.
6. Vouwen KH, Priev C. Blinded by the light: the growing complexity of p53. Cell. 2009;137(3):413–31.
7. Kresse JP, Gu W. Modes of p53 regulation. Cell. 2009;137(4):609–22.
8. Leroy B, Fourrier JL, Ishioka C, Monti P, Inga A, Fronza G, Soussi T. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res. 2013;41(Database issue):D662–9.
9. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–9.
10. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell. 2007;11(4):303–12.
11. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barucco R, Barsotti A, Chica A, Li W, Polotskaia A, et al. Mutant p53 disrupts mammalian tissue architecture via the mevalonate pathway. Cell. 2012;148(1–2):244–58.
12. Weissmueller S, Manchado E, Saborowski M, Morris JP, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous POGF receptor beta signaling. Cell. 2014;157(2):382–94.
13. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A. 2010;107(12):496–51.
14. Liu J, Ma Q, Zhang D, Wang X, Zhang D, Li W, Wang F, Wu E. Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer. 2012;48(15):3236–48.
15. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene. 2012;31(3):302–12.
16. Chi YH, Haller K, Peloponese JM Jr, Jeang KT. Histone acetyltransferase hALP and nuclear membrane protein hsSUN1 function in de-condensation of mitotic chromosomes. J Biol Chem. 2007;282(37):27447–58.
17. Larrieu D, Britton S, Demir M, Rodriguez R, Jackson SP. Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science. 2014;346(6213):527–32.
18. Liu X, Tan Y, Zhang C, Zhang Y, Zhang L, Ren P, Deng H, Luo J, Ke Y, Du X. NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2. EMBO Rep. 2016;17(3):349–66.
19. Pluk H, Soffnier J, Lührmann R, van Vrooijen WJ. DNA cloning and characterization of the human U3 small nucleolar ribonucleoprotein complex-associated 55-kilodalton protein. Mol Cell Biol. 1998;18(1):488–98.
20. Yan W, Chen X. Identification of GRO1 as a critical determinant for mutant p53 gain of function. J Biol Chem. 2009;284(18):12178–87.
21. Yan W, Liu G, Scourmanne A, Chen X. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations. Cancer Res. 2008;68(16):7859–66.
22. Terzian T, Suh YJ, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS, Lozano G. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev. 2008;22(10):1337–44.
23. Lukashchuk N, Vouwen KH. Ubiquitination and degradation of mutant p53. Mol Cell. 2007;27(23):2894–8.
24. Muller PA, Vouwen KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304–17.
25. Ito S, Horioka S, Suzuki T, Kawashcu H, Tanaka Y, Human NAT10 is an ATP-dependent RNA acetyltransferase responsible for N-acetylcysteine formation in 18 S ribosomal RNA (rRNA). J Biol Chem. 2014;289(52):35724–30.
26. Liu H, Ling Y, Gong Y, Sun Y, Hou L, Zhang B. DNA damage induces N-acetyltransferase NAT10 gene expression through transcriptional activation. Mol Cell Biochem. 2007;300(1–2):249–58.
27. Esse C, Scheffner M, Hofhfeld J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem. 2005;280(29):27443–50.
28. Tan TZ, Miow QH, Huang RY, Wong MK, Ye J, Lau JA, Wu MC, Bin Abdul Hadi LH, Soong R, Choolani M, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med. 2013;5(7):1051–66.
29. Muller PA, Vouwen KH. p53 mutations in cancer. Nat Cell Biol. 2013;15(1):2–8.
30. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268–86.
31. Dittmer D, Pali S, Zambrutti G, Chus S, Tereky AK, Moore M, Finlay C, Levine AJ. Gain of function mutations in p53. Nat Genet. 1993;4(1):42–6.
32. Lang GA, Iwakuma T, Suh YJ, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LG, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004;119(6):861–72.
33. Doyle B, Morton JP. Delaney DW, Ridgway RA, Wilkins JA, Sansom OJ. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol. 2010;222(2):129–37.
34. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol. 2011;8(1):25–37.
35. Li D, Marshenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 2011;18(12):1904–13.
36. Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase B. Oncogene. 2013;32(5):599–609.
37. Yi WY, Kang HJ, Kim HJ, Kong Y, Brown ML, Bae I. Targeting mutant p53 by a SRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget. 2013;4(7):1984–94.